Evotec, Active Biotech Ink Screening Pact
Evotec AG announced it has entered into a collaboration with Active Biotech AB to identify small-molecule modulators of a priority biological target, selected by the latter company, involved in immune disorders and cancer.
The former company, a novel small-molecule drugs discovery and development company, will use its technologies in assay development, high-throughput screening and surface plasmon resonance screening for the identification and validation of novel hits. It will screen its Lead Discovery Library, a small-molecule collection, to maximize the probability of finding medicinal chemistry starting points.
Active Biotech, of Lund, Sweden, is an autoimmune and inflammatory diseases and cancer biotechnology company.
For more information, visit: www.evotech.com
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024